RFL stock forecast, quote, news & analysis

Key Takeaways

• Rafael Holdings (RFL) shares declined roughly 27.6% over the last 30 days, falling from about $1.52 to around $1.10.
• The slide extends a sell-off that began after the company's pivotal Phase 3 TransportNPC trial missed its primary endpoint in late September.
• Fiscal Q4 and full-year results reported on October 29 showed revenue of about $874,000 and a net loss of roughly $29.6 million, alongside going-concern disclosure.
• Cash and cash equivalents fell to approximately $22.1 million at fiscal year-end, down from about $52.8 million a year earlier.
• The company submitted a New Drug Application (NDA) to the FDA for remibetadex in late October, a key regulatory milestone despite the mixed trial data.
• Several law firms announced investigations into potential securities claims, adding to investor uncertainty.
• For additional data, explore this ticker's Price Targets, Earnings, and Forecast pages.
• Discover automated trading ideas through Trending AI Robots.

Rafael Holdings (RFL) Company Overview and Market Position

Rafael Holdings, Inc. is a Newark, New Jersey-based biopharmaceutical holding company that owns interests in clinical and early-stage pharmaceutical and medical-device companies in the United States and Israel. It operates across three segments: Healthcare, Infusion Technology, and Real Estate. The company's lead asset is Trappsol Cyclo (remibetadex), an intravenous hydroxypropyl-beta-cyclodextrin being developed for Niemann-Pick Disease Type C (NPC), a rare, progressive and often fatal genetic disorder. Its pipeline also includes earlier-stage oncology programs such as CPI-613 (devimistat) and Promitil.

As a clinical-stage company with limited product revenue, Rafael Holdings is closely followed by investors for binary catalysts tied to its drug-development milestones and regulatory progress. Because it has no approved products generating meaningful sales, the stock is highly sensitive to clinical trial results, FDA interactions, and its ability to secure additional financing.

Rafael Holdings (RFL) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, Rafael Holdings shares have fallen approximately 27.6%, declining from a closing price of about $1.52 to around $1.10. The move was not a single-day event but rather a steady drift lower punctuated by renewed selling around the company's late-October earnings report and regulatory update.

The broader three-month trend has been considerably weaker. From roughly $1.97 in mid-August, the stock has declined roughly 44% through early November. The most severe single-session move occurred on September 30, when shares fell about 35% to close near $1.32 after the company disclosed that its Phase 3 TransportNPC study did not achieve statistical significance on its primary endpoint. That gap down reset the stock's valuation and set the tone for the subsequent gradual decline.

What Drove RFL Stock Price in the Last 30 Days

The most significant 30-day catalyst was the company's October 29 announcement of fiscal fourth-quarter and full-year 2026 results, combined with its corporate update. Revenue for the fiscal year ended July 31, 2026 was approximately $874,000, down from about $917,000 in the prior year, while the net loss attributable to the company was roughly $29.6 million. Critically, management disclosed that cash and cash equivalents had declined to about $22.1 million from roughly $52.8 million a year earlier and that, based on expected expenses tied to the FDA review and potential commercialization of remibetadex, there is substantial doubt about the company's ability to continue as a going concern without additional financing.

Around the same time, the company confirmed that its subsidiary Cyclo Therapeutics had submitted an NDA to the FDA for remibetadex for the treatment of NPC. While a meaningful regulatory step, the filing was received cautiously because it rests on a trial that missed its primary endpoint, even though prespecified subgroup and survival analyses showed favorable signals.

Compounding the pressure, several law firms — including Pomerantz LLP and Bronstein, Gewirtz & Grossman — announced investigations into potential securities claims on behalf of investors. The resulting uncertainty, combined with the reduced cash position and a lack of near-term positive catalysts, kept selling pressure elevated through the period.

What Drove RFL Stock Performance Over the Last Quarter

The quarterly decline was anchored by the September 30 disclosure of topline results from the pivotal Phase 3 TransportNPC study in 94 patients with NPC. The trial's primary endpoint — change in the four-domain NPC Clinical Severity Scale at Week 96 — did not reach statistical significance in the overall population (p=0.19). Investors had positioned for a clearer outcome, and the miss triggered a single-session drop of about 35%.

The data were not uniformly negative. A prespecified analysis of patients receiving background miglustat and/or leucine therapy — roughly 83% of the study population — showed a statistically significant 71% relative reduction in disease progression (p=0.046), and an overall survival analysis suggested a substantial reduction in mortality risk in infantile-onset patients compared with matched external controls. Despite these supportive signals, the broader market focused on the missed primary endpoint and the heightened regulatory and financing risk it introduced, driving the multi-month decline that followed.

Trending AI Robots

Tickeron's Trending AI Robots page curates a selection of automated trading bots drawn from a much larger universe of hundreds of AI-driven strategies that track thousands of tickers. Only the top-performing and most relevant bots are featured in this section, giving traders a focused view of strategies that are currently generating interest. These bots vary widely in approach, timeframe, and performance metrics, so the section can serve as a starting point for exploring different automated trading styles rather than a one-size-fits-all signal. Visitors interested in systematic, rules-based trading ideas can browse the page to see which strategies are gaining traction.

RFL Stock Forecast Drivers: What Investors Should Watch Next

Investors are likely to monitor several forward-looking factors. The first is the FDA's response to the remibetadex NDA, including whether the agency accepts the application for filing and whether it grants priority review or designates a PDUFA target action date. The strength of the subgroup and survival data relative to the missed primary endpoint will be central to that decision.

Financing is another key variable. With roughly $22.1 million in cash and explicit going-concern language in the latest filing, the company's ability to raise additional capital will influence its runway through the regulatory review process. Litigation developments tied to the announced law-firm investigations, any further clinical or regulatory updates, and broader biotech-sector risk appetite are also likely to shape sentiment. These factors carry inherent uncertainty, and none of them should be read as a prediction of future share-price direction.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations